KR101810292B1 - A composition for treating or preventing tuberculosis comprising Conjugated(10E,12Z)-Linoleic acid - Google Patents

Abstract

In the present invention, 10E, 12Z conjugated linoleic acid is a physiologically active substance contained in various medicinal plants, copper, and plants, and thus the antituberculous effect on tuberculosis has not been reported. In the present invention, it has been confirmed that the substance has antimicrobial activity or antibacterial effect against Mycobacterium tuberculosis and it can be used as a composition for treatment, improvement or prevention of tuberculosis using the same.
The present invention relates to a pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient, a health food composition for prevention or improvement, an animal pharmaceutical composition for treatment, improvement or prevention, Prevention or improvement of the composition. The pharmaceutical composition, health food composition, feed composition, animal medicine composition and quasi-drug composition according to the present invention have antimicrobial activity or antibacterial effect against Mycobacterium tuberculosis and thus can be used as an antimicrobial composition for treating, improving or preventing tuberculosis.

Description

TECHNICAL FIELD The present invention relates to a composition for treating or preventing tuberculosis comprising conjugated linoleic acid as an active ingredient, a composition for treating or preventing tuberculosis comprising conjugated (10E, 12Z) -linoleic acid,

The present invention relates to a pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing 10E, 12Z conjugated linoleic acid (Conjugated (10E, 12Z) -Linoleic acid) as an active ingredient, a health food composition for prevention or improvement, , An animal pharmaceutical composition for the treatment, improvement or prevention, and a quasi-product composition for prevention or improvement. More specifically, 10E, 12Z conjugated linoleic acid (Conjugated (10E, 12Z) -Linoleic acid) is a natural substance-derived active fatty acid and a substance exhibiting physiological activity contained in various kinds of animals and plants, and is a single substance 10E, 12Z conjugated linoleic acid (10E, 12Z) -Linoleic acid inhibits the proliferation and growth of Mycobacterium tuberculosis (Mtb) and has an anti-tuberculosis effect. Therefore, a pharmaceutical composition for treating, improving or preventing tuberculosis, a health food composition for prevention or improvement, Or improving animal feed compositions for the treatment, improvement, or prevention of diarrhea, and quasi-drugs for prevention or improvement.

Hundreds of years ago, infectious diseases such as smallpox, measles, cholera, flu virus, pulmonary tuberculosis and plague were high-risk infectious diseases that caused rapid deaths in all human beings, including children and adults. These infectious diseases have killed tens of millions of people over the centuries, and to date there are still some difficulties in controlling infectious diseases. Among the researches for the inhibition of infectious diseases, the discovery of penicillin has become a turning point in inhibiting or treating pathogenic microorganisms caused by antibiotics, inhibiting disease and improving health health and prolonging life span. However, direct or indirect damages caused by pathogenic microorganisms still cause various problems and diseases in economy, environment, medicine and health.

In particular, tuberculosis is an infectious disease that has taken the greatest number of lives since the discovery of traces in the fossil of the Stone Age around 7000 BCE. Tuberculosis became known to the world in 1882 when the German physician and bacteriologist Heinrich Hermann Robert Koch (1843-1910) discovered mycobacterium tuberculosis (Mtb), the pathogen of tuberculosis, It is distributed throughout the world, including underdeveloped countries in Africa and South America, and is causing the risk of infection. Tuberculosis is a communicable disease caused by infection of Mycobacterium tuberculosis. It spreads through contact between humans and humans and is infected by cough and droplets of tuberculosis patients. According to a report by the World Health Organization (WHO), about one-third of the world's population is now infected with tuberculosis, and 1.5 million people die annually from tuberculosis. According to the Nature Journal in 2013, the rate of tuberculosis infection (co-infection) in AIDS patients has gradually increased slightly since 1990.

Currently, anti-tuberculosis drugs such as Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide have been used in clinical trials, but most of them have been developed before 1970. Rifampicin (long-term use) Nephropathy, nephropathy, peripheral neuropathy, nephropathy, hyperglycemia, renal failure, dysuria, Ethambutol, optic neuritis, neurodegenerative diseases, neurodegenerative disorders, , Vision impairment, hallucinations, liver disorders, gastrointestinal disorders, pyrazinamide, hepatitis, jaundice, liver disorder, hyperuricemia, fever) and at the same time mutagenic drug resistance. In particular, multidrug-resistant tuberculosis (MDR-TB), which is resistant to rifampicin and isoniazid, can not be treated with the first-line antituberculous drug. Secondary anti-tuberculosis drugs Administration has been associated with serious side effects and has caused various problems in the recovery of the patients' health. These multidrug-resistant Mycobacterium tuberculosis are causing national health improvement and public health problems. Despite the recent advances in medical diagnostic technology and therapeutic technology, new tuberculosis patients are increasing in the 20s and 30s, who have been immunized by diet, through latent infections and chronic infections.

For this reason, the development and dissemination of new anti-tuberculosis drugs which are more effective and have less side effects are urgently required. Currently, various tuberculosis drugs are being actively developed around multinational pharmaceutical companies around the world, but effective first- and second- and third-line anti-tuberculosis drugs that can replace existing therapeutic drugs have not been developed yet.

Tuberculosis is also a serious livestock epidemic disease in the livestock industry due to serious infectious diseases not only in humans but also in various animals including cattle, goats, pigs and birds. In particular, bovine tuberculosis can develop into a respiratory or digestive tract of bovine tuberculosis, and infect people through tuberculosis infected cattle saliva or excreta. Currently, anti-tuberculosis medicines such as Rifampicin and Isoniazid, which are used in humans, are used for treatment of livestock infected with bovine tuberculosis. However, infected livestock is totally slaughtered to prevent transmission to human. For this reason, anti-tuberculosis drug plays a very important role not only in human beings but also in animal husbandry.

Most of the currently used anti-tuberculosis agents are produced through chemical synthesis, and thus exhibit many limitations such as causing the above-mentioned resistance and side effects. Therefore, in recent years, researches for separating and developing new anti-tuberculosis active materials from natural products including animals, plants, microorganisms and various herbal medicines and medicinal plants have been actively carried out, and the development of environmentally friendly substances has become an important issue. However, research and development of these new antimicrobial substances is not easy. In order to develop a new antimicrobial substance, it should be considered that the antimicrobial effect is wide, it has an effect on the existing resistant strains, has an effect on latent infection and chronic infection, and should be safe even without long term administration.

From this viewpoint, 10E, 12Z conjugated linoleic acid is an active fatty acid or a physiologically active substance derived from a natural product contained in various kinds of animals and plants existing in nature and has antioxidant, antiallergic, antidiabetic effect, cholesterol reduction, anti- Infarction, and inhibition of arteriosclerosis have been reported. It is reported to have activity such as decrease of body fat and promotion, and it is contained in large amount in plants and marine life. 10E, 12Z conjugated linoleic acid is a safe compound without acute toxicity and chronic toxicity.

Artemisinin and Artesunate, the therapeutic drugs of malaria, one of the World Infectious Diseases designated by the World Health Organization (WHO), are physiologically active substances extracted from the herbal medicine dog mugwort. Artemisinin-based Combination Therapy (ACT) for the treatment of Artemisinin-resistant malaria also uses Artemisinin and Artesunate as basic drugs. Recently, Korean pharmaceutical companies research and develop new malaria drugs, supply them to WHO, and sell them to Africa and Korea.

Under these circumstances, the present inventors have made efforts to study and develop antimicrobial active substances derived from natural materials. Conjugated (10E, 12Z) -Linoleic acid known as fatty acid inhibits the growth and proliferation of Mycobacterium tuberculosis, Confirming that it exhibits antibacterial effect against Mycobacterium tuberculosis and mycobacterium tuberculosis activity.

It is an object of the present invention to provide a pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient.

Another object of the present invention is to provide a health food composition for preventing or ameliorating tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient.

It is still another object of the present invention to provide a feed composition for preventing or improving tuberculosis comprising 10E, 12Z conjugated linoleic acid as an active ingredient.

Another object of the present invention is to provide an animal pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient.

Still another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient.

In one aspect of the present invention, the present invention provides a pharmaceutical composition for treating, improving or preventing tuberculosis comprising 10E, 12Z conjugated linoleic acid as an active ingredient.

The term " Conjugated (10E, 12Z) -Linoleic acid "as used in the present invention refers to" 10E, 12Z) -10,12-Octadecadienoic acid "or" Linoleic acid (10- , Z12-CLA ". It is a colorless solution at room temperature. It has a chemical formula of C ₁₈ H ₃₂ O ₂ and a molar mass of 280.45 g / mole.

In the present invention, 10E, 12Z conjugated linoleic acid was dissolved in ethanol, and a solution was prepared for each concentration by using a medium. The antimicrobial activity of a test substance against Mycobacterium tuberculosis was measured using a Resazurin microtiter assay. In one embodiment of the present invention, 10E, 12Z conjugated linoleic acid showed antibacterial activity against Mycobacterium tuberculosis (Fig. 1).

In the present invention, 10E, 12Z conjugated linoleic acid was dissolved in ethanol, the solution was prepared by using the medium, and the antimicrobial activity or the antibacterial effect of the test substance against Mycobacterium tuberculosis was measured using the MGIT SYSTEM measurement method. In one embodiment of the present invention, it was confirmed that 10E, 12Z conjugated linoleic acid exhibited antibacterial activity or antibacterial effect against Mycobacterium tuberculosis (Fig. 2).

The term " mycobacterium tuberculosis "as used in the present invention is classified as a human tubercle bacillus, a bovine type tubercle bacillus, a western type tubercle bacillus, and a bird type bacillus. It is an aerobic gram-positive bacterium in the form of a very fine rod-shaped bacterium with a width of 4.0 m and a width of 0.3 to 0.5 m. Mycobacterium tuberculosis is classified into four types A, I, B and C, pH 6.8 ~ 7.0 and temperature 37 is the optimal growth condition.

The term " tuberculosis "as used herein refers to a disease that is directly infected by a fine needle or droplet from the respiratory tract from a patient with M. tuberculosis infection, and is by definition an infection caused by M. tuberculosis. Currently, tubercle bacillus is well-developed in lung tissue because it is transmitted through air. Thus, tuberculosis usually refers to pulmonary tuberculosis. However, tuberculosis can invade most tissues and organs such as pleura, lymph node, spine, brain, nerve, kidney, gastrointestinal tract, genitalia, bone and muscle as well as lung.

Tuberculosis may be caused by tuberculosis or tuberculosis according to organs such as tuberculosis, hip tuberculosis, bone tuberculosis, pelvic tuberculosis, testicular tuberculosis, bladder tuberculosis, renal tuberculosis, tuberculosis, skin tuberculosis, tuberculosis, laryngeal tuberculosis, tuberculosis, Tuberculosis, tuberculous peritonitis, tuberculous ovarian tuberculosis, and chronic tuberculosis. Mycobacterium tuberculosis grows slowly using the nutrients in the body of the host, and when it is caught in tuberculosis, symptoms such as lack of energy, easy fatigue, and decrease in body weight appear. In addition, symptoms vary according to the organ that is infected with Mycobacterium tuberculosis. In pulmonary tuberculosis, symptoms such as cough, sputum and chest pain occur, and urinary frequency, urination difficulty and hematuria occur in tuberculosis of urography. In osteoarthritic tuberculosis, If tuberculosis, the lymph nodes of the whole body, especially the neck or armpit, grow, causing pain and pressure. In addition, back pain in patients with spinal tuberculosis, central nervous system tuberculosis symptoms such as headache and vomiting appear. When a person's body is infected with Mycobacterium tuberculosis, the normal tissue of the body is destroyed at a very slow rate by the inflammatory reaction with immune cells, and a cheese-like pus is formed and granuloma (lumps) do.

The term " antibacterial "as used in the present invention means an effect against bacteria, more specifically, an effect of inhibiting the growth of bacteria and fungi by a drug, a physiologically active substance or a known chemical substance. For the purpose of the present invention, Inhibiting growth and inhibiting growth.

The tuberculosis that can be treated, improved or prevented by the pharmaceutical composition of the present invention is not limited thereto, but it may be preferably pulmonary tuberculosis, more preferably infectious tuberculosis caused by infection with Mycobacterium tuberculosis.

In the present invention, the therapeutic, ameliorative or preventive effect of the pharmaceutical composition on tuberculosis may be achieved by having antimicrobial activity or antibacterial effect which inhibits proliferation and growth of Mycobacterium tuberculosis. In one embodiment of the present invention, 10E, 12Z conjugated linoleic acid was found to have antimicrobial activity or antimicrobial effect inhibiting the growth and proliferation of Mycobacterium tuberculosis through the Resazurin microtiter assay and the MGIT SYSTEM assay, Treatment, improvement or preventive effect can be achieved (Figs. 1 to 2).

The 10E, 12Z conjugated linoleic acid of the present invention is not limited thereto, but may preferably be a synthetic material obtained by chemical synthesis or a material derived from an animal, a plant or a natural product. 10E, 12Z conjugated linoleic acid can be obtained by an ordinary extraction method, a separation method, or a purification method derived from synthetic methods, animals, plants or natural products known in the art. The extraction method may be, but not limited to, organic solvent extraction, hot water extraction, hot water extraction, cold extraction, steam reflux extraction, reflux cooling extraction, ultrasonic extraction, vacuum concentration or freeze- have.

As used herein, the term "prevention" means any action that inhibits or delays the onset of the disease by ingestion or administration of the composition, and "treatment" means that the ingestion or administration of the composition It means all acts that are benefited.

As used herein, the term "improvement" refers to the administration of a composition comprising 10E, 12Z conjugated linoleic acid as an active ingredient to alleviate the onset or symptom of the disease or to inhibit or reduce the growth and proliferation of Mycobacterium tuberculosis, Of the symptoms.

The pharmaceutical composition of the present invention may include, but is not limited to, a pharmaceutically acceptable carrier.

Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include dextrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, poly Vinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, and mineral oil. Compositions comprising a pharmaceutically acceptable carrier can be of various oral or parenteral formulations. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration may include tablet pills, powders, granules, capsules, and the like, which may contain one or more excipients, such as starch, calcium carbonate, sucrose, or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, amino acids, emulsions, lyophilized formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

In addition, the pharmaceutical composition of the present invention may be in the form of tablets, pills, powders, granules, capsules, sustained release formulations, suspensions, suspensions, solutions, emulsions, injections, It may have any one form selected from the group consisting of a patch, a film, a coating agent, a patch, an inhalant, a syrup, an emulsion, a gel, an ointment, eye drops, a sterilized aqueous solution, a nonaqueous agent, a lyophilized agent, a suppository or an aerosol And the form of the formulations which can be produced by the above examples is not limited.

The dosage form of the pharmaceutical composition of the present invention is not particularly limited and may be varied depending on the degree of absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, have. The pharmaceutical composition of the present invention is prepared in consideration of an effective dose range, and the formulated unit dosage form can be prepared by using a specialized dosage regimen according to the judgment of the expert and the needs of the individual, Lt; / RTI >

In another aspect, the present invention provides a health food composition for preventing or ameliorating tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient. The health food composition may preferably be obtained by having an antibacterial activity or antibacterial effect against Mycobacterium tuberculosis, as described above.

When the composition of the present invention is used as an additive for food, the composition may be added as it is or may be used together with other health food or ingredients thereof, and may be suitably used according to a conventional method. The mixing amount of the active ingredient can be suitably determined according to the purpose of use, and the amount of the food composition of the present invention is not particularly limited.

The food of the present invention is not particularly limited and examples of the health food to which the composition can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gum, Dairy products, various soups, beverages, tea, juice, drinks, alcoholic beverages and vitamin complexes, and may include foods used as food for animals, which may include all health foods in a conventional sense.

In addition, when the health food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as an additional ingredient such as ordinary drinks. In addition to the above, the health food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, it may contain flesh for the production of natural fruit drinks, fruit juice drinks and vegetable drinks. The composition of the present invention can be prepared in the form of tea, juice, and drink, and then consumed for drinking, granulated, tableted, encapsulated, and powdered, but the form that can be manufactured by the above example is not limited.

In another aspect, the present invention provides a feed composition for preventing or improving tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient. The feed composition may preferably be obtained by having an antibacterial activity or an antibacterial effect against Mycobacterium tuberculosis, as described above.

When the composition of the present invention is used as a feed additive, the composition may be added as it is or may be mixed with other feed ingredients and used appropriately according to a conventional method. The amount of the active ingredient to be mixed may be appropriately determined according to the purpose of use, and the amount of the feed composition of the present invention is not particularly limited.

There is no particular limitation on the kind of the feed of the present invention, and the composition may be supplemented with various auxiliaries such as amino acids, inorganic salts, vitamins, antioxidants, microbial preparations and the like and pulverized or crushed wheat, vegetable protein feeds such as barley, corn, Can be used in combination with nutritional supplements, growth promoters, digestion-absorption promoters, and disease prevention agents in addition to the main components such as animal protein feeds, animal fat and vegetable fat. The dosage form, method and formulation of the feed can be varied, and the form that can be produced by the example is not limited.

The feed composition of the present invention can be applied to a large number of animal diets, i.e. feeds, including mammals, poultry, fish and crustaceans. Commercial livestock can be used for zoo animals such as mammals, elephants, camels, giraffes, monkeys, pets such as cows, pigs, horses, deer and goats; pets such as dogs and cats; , Pigeons, and commercially available fish and crustaceans such as carp, carp, trout, mullet, and shrimp.

In another aspect, the present invention relates to an animal pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient. That is, the composition of the present invention can be used as an animal pharmaceutical composition for the purpose of treatment, improvement or prevention of tuberculosis.

The composition may preferably be achieved by having an antibacterial activity or an antibacterial effect against Mycobacterium tuberculosis, as described above.

When the composition of the present invention is used as an animal pharmaceutical composition, the composition may be used as it is or may be used together with other pharmaceutical or quasi-drug components, and may be suitably used according to a conventional method, but is not limited thereto. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health, improvement or therapeutic treatment).

In another aspect, the present invention relates to a quasi-drug composition for preventing or improving tuberculosis containing 10E, 12Z conjugated linoleic acid as an active ingredient. That is, the composition of the present invention can be added to a quasi-drug composition for preventing or improving tuberculosis.

The composition may preferably be achieved by having an antibacterial activity or an antibacterial effect against Mycobacterium tuberculosis, as described above.

When the composition of the present invention is used as a quasi-drug additive, the composition may be added as it is or may be used together with other quasi-drugs or quasi-drugs, and may be suitably used according to a conventional method, but is not limited thereto. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health, or improvement). The composition of the quasi-drug composition of the present invention is not limited, but it is preferable to use a disinfectant, a shower foam, a goggle, a wet tissue, a detergent soap, a spray, a hand wash, an ointment, A sanitary pad, a sanitary napkin, a condom, a band, a filter filler, a sanitary glove, a sanitary container, a sanitary bag or a mask, and the form that can be manufactured by the above example is not limited.

The pharmaceutical composition, health food composition, feed composition, animal medicine composition or quasi-drug composition according to the present invention have antimicrobial activity or antibacterial effect against Mycobacterium tuberculosis, so that they can be effectively used for treatment, improvement or prevention of tuberculosis. . ≪ / RTI >

Fig. 1 shows the result of measuring the antibacterial activity of each test substance against the Mycobacterium tuberculosis by applying 10E, 12Z conjugated linoleic acid to a Resazurin microtiter assay. "+" Indicates the antibacterial activity or antibacterial effect of the test substance against Mycobacterium tuberculosis.
Fig. 2 shows the result of measuring the antibacterial effect of each test compound on the Mycobacterium tuberculosis by applying 10E, 12Z conjugated linoleic acid to MGIT SYSTEM measurement method.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

: material

Middlebrook 7H9 Broth (Difco), Middlebrook OADC Enrichment supplement solution, MGIT 7ml Tube and MGIT Supplement (OADC) were purchased from Becton Dickinson (USA). Rifampicin, Isoniazid, Tween 80, Glycerol, DMSO (Dimethyl Sulfoxide), ethanol and Resazurin sodium salt powder were purchased from Sigma-Aldrich Co. LLC, St. Louis, Mo., USA.

: Culture of Mycobacterium tuberculosis

Middlebrook 7H9 medium containing 0.05% Tween 80 or 0.2% glycerol and 10% OADC Enrichment was used as a liquid medium for culturing Mycobacterium tuberculosis (H37Rv, ATCC 27294). The medium was incubated at 37 ° C. with shaking after inoculation with Mycobacterium tuberculosis. The culture of Mycobacterium tuberculosis was continued until the absorbance reached 0.09 (McFarland turbidity standard 0.5) at 600 nm. After incubation, the cells were subcultured and stored at -80 ℃ for freezing.

: Measurement of antimicrobial activity by Resazurin microtiter assay (REMA)

To confirm the antimicrobial activity of 10E, 12Z conjugated linoleic acid against Mycobacterium tuberculosis, a single substance was dissolved in ethanol and prepared by concentration using the medium. Rifampicin and Isoniazid were used as drug control drugs. After culturing, the Mycobacterium tuberculosis was diluted with Middlebrook 7H9 medium to have a concentration of 2 × 10 ⁶ CFU / ml. The test substance was added to the culture medium of Mycobacterium tuberculosis in a concentration of 25 μg / ml and 50 μg / ml , 100 μg / ml and 200 μg / ml, respectively, and 200 μl of the solution was added to a 96-well plate. Rifampicin and Isoniazid were added to the culture medium of Mycobacterium tuberculosis at a concentration of 10 μg / ml, and then added to a 96-well plate. The 96-well plate was incubated at 37 ° C. for 5 days Respectively. Five days after the incubation, 30 μl of a coloring solution (0.02% resazurin solution) was added to each well of a 96-well plate, and the plate was incubated at 37 ° C. for 36 hours. After 36 hours, the antimicrobial activity of each test drug was compared with the negative control, the positive control and the drug control. (Blank Control Group), a positive control group (Untreated Positive Growth Control Group), a drug control group, which received Rifampicin and Isoniazid as a drug control group (Drug-Treated Group) were cultured together to measure the antibacterial activity of test substances against Mycobacterium tuberculosis.

As a result, it was confirmed that the test substance 10E, 12Z conjugated linoleic acid exhibited a very high antibacterial activity against Mycobacterium tuberculosis through an experiment of antibacterial activity by the liquid culture method (Fig. 1). These results indicate that 10E, 12Z conjugated linoleic acid can be used as an antimicrobial composition against Mycobacterium tuberculosis.

: Measurement of antimicrobial effect by MGIT SYSTEM measurement method

In order to confirm the antimicrobial effect of 10E, 12Z conjugated linoleic acid on the Mycobacterium tuberculosis, the above test substance was dissolved in ethanol, prepared by concentration using the medium, and then applied to the MGIT SYSTEM measurement method to measure the antibacterial effect of the test substance on the Mycobacterium tuberculosis. In other words, the group (Untreated Positive Growth Control), which was only a positive control group, was cultured with Drug-treated Control (Rifampicin and Isoniazid) at 10 ㎍ / ㎖ The effect of anti - tubercle bacilli was measured and cultured for 4 weeks.

The procedure of the MGIT SYSTEM measurement method is as follows. First, 0.8 ml of MGIT supplement solution (OADC, Becton Dickinson, USA), 0.1 ml of Mycobacterium tuberculosis solution and test substance solution were added to each MGIT 7 ml tube (Becton Dickinson, USA) Ml. After mixing, the tube is mounted on a BACTEC MGIT 960 system (Becton Dickinson, USA) and cultured. Mycobacterium tuberculosis was cultured in Middlebrook 7H9 medium and added to the tube adjusted to 1,200,000 CFU / ml based on a total volume of 8 ml. The MGIT system is equipped with a fluorescence measurement sensor that automatically measures the growth and proliferation of Mycobacterium tuberculosis in the incubator and the susceptibility of Mycobacterium tuberculosis or Mycobacterium tuberculosis is automatically detected and measured according to the proliferation and growth of Mycobacterium tuberculosis.

As a result, it was confirmed through the MGIT SYSTEM measurement method that 10E, 12Z conjugated linoleic acid, which is a test substance, showed a very high antimicrobial activity or antimicrobial effect in a dose-dependent manner to the Mycobacterium tuberculosis (Fig. 2). These results indicate that 10E, 12Z conjugated linoleic acid can be used as an antimicrobial composition against Mycobacterium tuberculosis.

As described above, the measurement results of the test materials of the present invention are shown in FIGS. 1 and 2. FIG.

The pharmaceutical composition, health food composition, feed composition, animal medicine composition and quasi-drug composition according to the present invention have antimicrobial activity or antibacterial effect against Mycobacterium tuberculosis, so that they can be used for treatment, improvement or prevention of tuberculosis and used for various antibacterial agents . The composition according to the present invention can be industrially usefully used in industrial fields such as pharmaceutical industry, food industry, agriculture industry and manufacturing industry.

In Fig. 1, "+" indicates the antibacterial activity or antibacterial effect of the test substance against Mycobacterium tuberculosis.

Claims (6)

10E, 12Z conjugated linoleic acid as an active ingredient.
The composition of claim 1, wherein the composition has an antibacterial activity against mycobacterium tuberculosis.
10E, 12Z A health food composition for preventing or ameliorating tuberculosis containing conjugated linoleic acid as an active ingredient.
10E, 12Z A feed composition for preventing or improving tuberculosis containing conjugated linoleic acid as an active ingredient.
10E, 12Z Animal pharmaceutical composition for the treatment, improvement or prevention of tuberculosis containing conjugated linoleic acid as an active ingredient.
10E, 12Z A quasi-drug composition for preventing or improving tuberculosis containing conjugated linoleic acid as an active ingredient.

Images